FDA Expands Transparency, Disclosure of KOL Involvement, Mirroring Pharma Trend
A recent Pharmaceutical Executive article outlined new US Food and Drug Administration draft guidance that would “expand transparency and disclosure when the agency grants a conflict of interest waiver to permit an individual’s participation at an FDA advisory committee meeting.” The FDA, much like the many public and private companies that make up the biopharmaceutical …
FDA Expands Transparency, Disclosure of KOL Involvement, Mirroring Pharma Trend Read More »
